Abstract
Introduction: Early radical cystectomy (eRC) can be performed for high or very high risk non-muscle-invasive bladder cancer (NMIBC). Whether immediate eRC is beneficial is still unclear. The objective of this study was to compare outcomes between immediate eRC, delayed eRC, and radical cystectomy (RC) at the diagnosis of muscle-invasive bladder cancer (MIBC). Methods: The single-center cohort consisting of patients with RC between 2008 and 2020 was divided into 4 populations: patients who received immediate eRC within 3 months of diagnosis of NMIBC (IEC), patients who received eRC at recurrence of NMIBC (REC), patients who underwent RC after primary diagnosis of MIBC (primMIBC), and patients with the initial diagnosis of NMIBC who received RC after progression to MIBC (progMIBC). Results: Among the 463 patients included, 39 had IEC, 58 had REC, 314 had primMIBC, and 53 had progMIBC. No statistically significant differences for OS, CSS, and RFS between the two groups receiving eRC were found. Patients with pT1 tumors (p = 0.003) and tumor size ≥3 cm (p = 0.012) were more likely to receive immediate RC. Conclusion: Immediate and delayed eRC show comparable survival outcomes. The present study emphasizes the need for accurate risk stratification of patients with NMIBC to identify the most advantageous therapy for individual patients.
Journal Section:
Research Article
References
1.
Bray
F
, Ferlay
J
, Soerjomataram
I
, Siegel
RL
, Torre
LA
, Jemal
A
. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2018
;68
(6
):394
–424
. 2.
Babjuk
M
, Burger
M
, Capoun
O
, Cohen
D
, Compérat
EM
, Dominguez Escrig
JL
, et al. European association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)
. Eur Urol
. 2022
;81
(1
):75
–94
. 3.
Sylvester
RJ
, van der Meijden
AP
, Lamm
DL
. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials
. J Urol
. 2002
;168
(5
):1964
–70
. 4.
van der Meijden
AP
, Sylvester
RJ
, Oosterlinck
W
, Hoeltl
W
, Bono
AV
; EORTC Genito-Urinary Tract Cancer Group
. Maintenance Bacillus calmette-guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial
. Eur Urol
. 2003
;44
(4
):429
–34
. 5.
Herr
HW
. The value of a second transurethral resection in evaluating patients with bladder tumors
. J Urol
. 1999
;162
(1
):74
–6
. 6.
Agarwal
PK
, Kamat
AM
. Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer
. Indian J Urol
. 2008
;24
(1
):77
–83
. 7.
Herr
HW
, Dotan
Z
, Donat
SM
, Bajorin
DF
. Defining optimal therapy for muscle invasive bladder cancer
. J Urol
. 2007
;177
(2
):437
–43
. 8.
Gontero
P
, et al. Guidelines on Non-muscle-invasive bladder cancer (Ta, T1 and CIS)
. In: EAU guidelines published at the 38th annual congress milan 2023
. Arnhem, the Netherlands
: European Associaton of Urology Guidelines Office
.9.
Gontero
P
, Sylvester
R
, Pisano
F
, Joniau
S
, Vander Eeckt
K
, Serretta
V
, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients
. Eur Urol
. 2015
;67
(1
):74
–82
. 10.
Cinar
NB
, Yilmaz
H
, Avci
IE
, Cakmak
K
, Teke
K
, Dillioglugil
O
. Reporting perioperative complications of radical cystectomy: the influence of using standard methodology based on ICARUS and EAU quality criteria
. World J Surg Oncol
. 2023
;21
(1
):58
. 11.
Zakaria
AS
, Santos
F
, Dragomir
A
, Tanguay
S
, Kassouf
W
, Aprikian
AG
. Postoperative mortality and complications after radical cystectomy for bladder cancer in Quebec: a population-based analysis during the years 2000-2009
. Can Urol Assoc J
. 2014
;8
(7–8
):259
–67
. 12.
Moschini
M
, Sharma
V
, Dell’oglio
P
, Cucchiara
V
, Gandaglia
G
, Cantiello
F
, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy
. BJU Int
. 2016
;117
(4
):604
–10
. 13.
Hurle
R
, Losa
A
, Manzetti
A
, Lembo
A
. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up
. Urology
. 1999
;54
(2
):258
–63
. 14.
Metwalli
AR
, Kamat
AM
. Controversial issues and optimal management of stage T1G3 bladder cancer
. Expert Rev Anticancer Ther
. 2006
;6
(8
):1283
–94
. 15.
Cogorno Wasylkowski
L
, Ríos-González
E
, Linares Espinós
E
, Leibar Tamayo
A
, Martínez-Piñeiro Lorenzo
L
. Indication for early cystectomy in nonmuscle-invasive bladder cancer. Literature review
. Actas Urol Esp
. 2018
;42
(1
):17
–24
. 16.
Freeman
JA
, Esrig
D
, Stein
JP
, Simoneau
AR
, Skinner
EC
, Chen
SC
, et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction
. Cancer
. 1995
;76
(5
):833
–9
. 17.
Hautmann
RE
, Volkmer
BG
, Gust
K
. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)
. World J Urol
. 2009
;27
(3
):347
–51
. 18.
Jäger
W
, Thomas
C
, Haag
S
, Hampel
C
, Salzer
A
, Thüroff
JW
, et al. Early vs delayed radical cystectomy for “high-risk” carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival
. BJU Int
. 2011
;108
(8 Pt 2
):E284
–8
. 19.
De Berardinis
E
, Busetto
GM
, Antonini
G
, Giovannone
R
, Gentile
V
. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy
. Int Urol Nephrol
. 2011
;43
(4
):1047
–57
. 20.
Sternberg
IA
, Keren Paz
GE
, Chen
LY
, Herr
HW
, Dalbagni
G
. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection
. BJU Int
. 2013
;112
(1
):54
–9
. 21.
Ali-El-Dein
B
, Al-Marhoon
MS
, Abdel-Latif
M
, Mesbah
A
, Shaaban
AA
, Nabeeh
A
, et al. Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder
. Urol Ann
. 2011
;3
(3
):127
–32
. 22.
Wan
JCM
. Survival outcomes of early versus deferred cystectomy for high-grade non-muscle-invasive bladder cancer: a systematic review
. Curr Urol
. 2020
;14
(2
):66
–73
. 23.
Diamant
E
, Roumiguié
M
, Ingels
A
, Parra
J
, Vordos
D
, Bajeot
AS
, et al. Effectiveness of early radical cystectomy for high-risk non-muscle invasive bladder cancer
. Cancers
. 2022
;14
(15
):3797
. 24.
Grossmann
NC
, Rajwa
P
, Quhal
F
, König
F
, Mostafaei
H
, Laukhtina
E
, et al. Comparative outcomes of primary versus recurrent high-risk non-muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study
. Eur Urol Open Sci
. 2022
;39
:14
–21
. 25.
Denzinger
S
, Fritsche
HM
, Otto
W
, Blana
A
, Wieland
WF
, Burger
M
. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach
. Eur Urol
. 2008
;53
(1
):146
–52
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
